Ticker Details
AbCellera Biologics Inc.
IPO Date:	December 11, 2020
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$3.67B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.38 | 3.61%
Avg Daily Range (30 D):	$0.42 | 5.70%
Avg Daily Range (90 D):	$0.32 | 5.15%

Institutional Daily Volume
Avg Daily Volume:	2.77M
Avg Daily Volume (30 D):	7.68M
Avg Daily Volume (90 D):	7.68M

Trade Size
Avg Trade Size (Sh.):	173
Avg Trade Size (Sh.) (30 D):	155
Avg Trade Size (Sh.) (90 D):	195

Institutional Trades
Total Institutional Trades:	1,558
Avg Institutional Trade:	$1.74M
Avg Institutional Trade (30 D):	$1.61M
Avg Institutional Trade (90 D):	$1.54M
Avg Institutional Trade Volume:	.18M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$1.91M
Avg Closing Trade (30 D):	$2.06M
Avg Closing Trade (90 D):	$1.75M
Avg Closing Volume:	206K

News

Aug 14, 2025 @ 11:23 AM Prelude Cuts Q2 Losses and Costs 13% Source: Jesterai

Jul 30, 2025 @ 5:00 PM Global Antibody Discovery Market to Observe Stupen... Source: Delveinsight

Jun 13, 2024 @ 9:40 AM Down 57%, Is AbCellera Biologics a Buy on the Dip?... Source: newsfeedback@fool.com (Cory Renauer)

May 8, 2024 @ 8:30 AM AbCellera Biologics (ABCL) Q1 2024 Earnings Call T... Source: newsfeedback@fool.com (Motley Fool Transcribing)

May 7, 2024 @ 10:05 PM AbCellera Biologics Inc. (ABCL) Reports Q1 Loss, M... Source: Zacks Equity Research

Financials
	TTM	Q2 2026	Q1 2026
Basic EPS	$-.54	$-.18	$-.14
Diluted EPS	$-.54	$-.18	$-.14
Revenue	$66.17M	$4.05M	$8.32M
Gross Profit
Net Income / Loss	$-164.66M	$-55.43M	$-43.17M
Operating Income / Loss	$-225.16M	$-62.78M	$-57.52M
Cost of Revenue
Net Cash Flow	$27.3M	$43.23M	$-51.45M
PE Ratio